| Sub Cat. No. |
Molecular Weight |
Glycan Name |
Functional Group |
Inquiry |
|
X25-05-YM737-1 |
PEG 350 Da |
Lentinan |
HAS |
Inquiry
|
|
X25-05-YM737-2 |
PEG 550 Da |
Lentinan |
HAS |
Inquiry
|
|
X25-05-YM737-3 |
PEG 750 Da |
Lentinan |
HAS |
Inquiry
|
|
X25-05-YM737-4 |
PEG 1 kDa |
Lentinan |
HAS |
Inquiry
|
|
X25-05-YM737-5 |
PEG 2 kDa |
Lentinan |
HAS |
Inquiry
|
|
X25-05-YM737-6 |
PEG 3 kDa |
Lentinan |
HAS |
Inquiry
|
|
X25-05-YM737-7 |
PEG 4 kDa |
Lentinan |
HAS |
Inquiry
|
|
X25-05-YM737-8 |
PEG 5 kDa |
Lentinan |
HAS |
Inquiry
|
|
X25-05-YM737-9 |
PEG 10 kDa |
Lentinan |
HAS |
Inquiry
|
|
X25-05-YM737-10 |
PEG 20 kDa |
Lentinan |
HAS |
Inquiry
|
Properties
Description
Lentinan-PEG-human serum albumin, called HAS-lentinan, embodies a serum protein-conjugated lentinan derivative connected through PEG spacers. This biocompatible construct combines plasma protein compatibility with lentinan's immunostimulatory actions and DPPS-related membrane fusion.
Glycan Structure
Its glycan structure is a β-(1→3)-linked d-glucose backbone with β-(1→6)-glucosyl side branches.
Source
Chemical synthesis
Impurities
No visible impurities to the naked eye.
Solubility
This product is soluble in most organic solvents, such as DCM, DMF, DMSO, and THF, and exhibits excellent solubility in water.
Identity
Confirmed by NMR.
Applications
Lentinan-PEG-human serum albumin can be used for its potential to develop HSA-PEG hybrids for extending circulatory half-life in pharmacokinetic profiling.